Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by GK52N106Won Apr 02, 2011 3:47pm
339 Views
Post# 18377627

Dean Peterson

Dean PetersonYou have to keep in mind, that many of you are reading this board and supporting, or not supporting SCT (i.e. pumping or bashing) and analyzing and forming an opinion about SCT on day to day goings on. They either like what they hear or they don`t, or they don`t hear anything at all and they get frustrated.

Dean Peterson is not operating SCT on a day to day basis. He`s not looking to release a news release just so that short term money or retail investors can make a quick dollar. Dean Peterson is very much `BIG PICTURE``, mapping out a plan for all 3 of SCT`s avenues and making sure he has people in place to look after the smaller picture details.

The new CEO will have much the same approach. That person will be a completely different person than the last good DOC. The new CEO will likely be a, or become an insider. Ìf you`ve met Dean, would you not say he is completely different than the last DOC. I am of the belief that if the last insider didn`t pull out last May, the share price wouldn`t have had as much as a dramatic drop.

Don`t expect news anytime soon. Infact the next news release could be a boring one a month away or it could be the termination of CDC.
Bullboard Posts